Subscribe to ExpertReview

The latest research, meeting updates and CME, in your inbox.

Hong Kong · Sponsored

Ribociclib plus Fulvestrant Improves Survival in Advanced Breast Cancer

12 Jan 2020Oncology

Christy HC CHEUNG, BSc

Share

This content is sponsored. It is intended for healthcare professionals only.

In patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, adding ribociclib to fulvestrant improved the overall survival (OS) by 28% compared to fulvestrant alone, as reported by Slamon et al. (2019) in The New England Journal of Medicine.

ADDING-RIBOCICLIB-TO-FULVESTRANT-IMPROVES-THE-SURVIVAL-OF-ADVANCED-BREAST-CANCER-PATIENTS-MONALEESA-3

For healthcare professionals

This sponsored content is for registered Hong Kong doctors. Log in or register to read it. If you received an access link, open it from your email.

Log inRegister

Related posts

Stylized illustration of a large blue immune cell with surface receptors and yellow nuclei, surrounded by smaller cells.Research · OncologyESCAT v2 adds graded certainty tiers and a resistance scale for molecular targetsAn international ESMO expert panel has revised the 2018 ESCAT framework, restructuring Tier I, Tier II and Tier X, formalising tumour-agnostic gating criteria and adding a four-level scale for resistance biomarkers.8 Nov 2026